• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Turkey·Healthcare·ECILC.IS
Share

EIS Eczacibasi Ilac, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. Stocks

TRY 62.3Last Updated 09.10.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

TRY 866.21M

TRY 62.3
Key Takeaways

Risk factor

Considerable default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

EIS Eczacibasi Ilaç, Sinai ve Finansal Yatirimlar Sanayi ve Ticaret A.S. is a Turkish enterprise, operating predominantly in the health and real estate development sectors through its various subsidiaries. Its Health division is responsible for the production and distribution of pharmaceutical goods for both human and veterinary applications. Concurrently, the Real Estate Development segment is engaged in property creation and offers consultancy pertaining to land development and project oversight. This company, established in Istanbul, Turkey, in 1951, functions as a subsidiary of Eczacibasi Holding A.S.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 21:40

Delta has postponed the launch of flights to Saudi Arabia due to Houthi attacks on airports

12.10.2026 20:43

One of the world's largest gold buyers is shifting to selling gold

12.10.2026 19:22

A Crisis-Proof Formula for Shaping the Future: Why the Nobel Prize in Economics Was Awarded

12.10.2026 19:20

Is it time to buy stocks? Goldman Sachs has upgraded its recommendation for the next three months

12.10.2026 18:58

Oppenheimer upgrades Fastly to ‘outperform’ ahead of 3Q earnings and GTA VI launch

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026